Sabena Sultan

Chief Tech/Sci/R&D Officer at Cell Therapy Ltd.

Consumer Services

Health Technology

Profile

Sabena Sultan is currently the Director & Global Head-Research at Cell Therapy Ltd.
Prior to this, he worked as a Principal Investigator at University College London and King's College London.
He holds a doctorate degree from Imperial College London.

Sabena Sultan active positions

Companies	Position	Start
Cell Therapy Ltd. Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.	Chief Tech/Sci/R&D Officer	-

All active positions of Sabena Sultan

Former positions of Sabena Sultan

Companies	Position	End
University College London	Corporate Officer/Principal	-
King's College London	Corporate Officer/Principal	-

See the detail of Sabena Sultan's experience

Training of Sabena Sultan

Imperial College London

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Sabena Sultan's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Cell Therapy Ltd. Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.	Health Technology